Apatinib Shows Promising Survival Advantage in Advanced Gastric Cancer
Apatinib demonstrated an improvement in overall survival (OS) by 1.8 months and an acceptable toxicity profile compared to placebo as treatment for advanced gastric cancer, according to findings published in the Journal of Clinical Oncology.
Read Source